Keros Therapeutics, Inc.
KROS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2,251% | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,234.5% | -100,779.5% | – | -280.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,277.5% | -101,319.2% | – | -292.3% |
| EPS Diluted | -5 | -5.2 | -4.15 | -2.52 |
| % Growth | 3.8% | -25.3% | -64.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |